At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Furosemide intravenous solution +2 moredrug
Likely dose
Furosemide intravenous solution 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide. A Randomized Controled Trial
In Brief
A Phase 2 clinical trial evaluating Furosemide intravenous solution, Chlortalidone, and 1 other intervention for Cardiorenal Syndrome. Completed, enrolled 80 participants across 2 sites.
Detailed Summary
In double-blind clinical trial, determine renal recovery with two different furosemide strategies in patients with type 1 cardiorenal syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiorenal Syndrome
CountriesMexico
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
Primary CompletionApr 2020
First PostedMay 2020
TodayJul 2026
First PostedMay 19, 2020
Enrollment StartJul 1, 2017
Primary CompletionApr 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.1 years ago
Interventions
Furosemide intravenous solutiondrug
Administrated as an 80 mg intravenous bolus every 24 hours in both arms and then as a continuous infusion dosed according to the experimental arm.
Chlortalidonedrug
One 50 mg pill administrated every 24 hours in group B
Spironolactonedrug
One 50 mg pill administrated every 24 hours in group B